Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activation.

Constitutively active mutant KRas displays a reduced rate of GTP hydrolysis via both intrinsic and GTPase-activating protein-catalyzed mechanisms, resulting in the perpetual activation of Ras pathways. We describe a fragment screening campaign using X-ray crystallography that led to the discovery of three fragment binding sites on the Ras:SOS complex. The identification of tool compounds binding at each of these sites allowed exploration of two new approaches to Ras pathway inhibition by stabilizing or covalently modifying the Ras:SOS complex to prevent the reloading of Ras with GTP. Initially, we identified ligands that bound reversibly to the Ras:SOS complex in two distinct sites, but these compounds were not sufficiently potent inhibitors to validate our stabilization hypothesis. We conclude by demonstrating that covalent modification of Cys118 on Ras leads to a novel mechanism of inhibition of the SOS-mediated interaction between Ras and Raf and is effective at inhibiting the exchange of labeled GDP in both mutant (G12C and G12V) and wild type Ras.

[1]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[2]  Paramjit S Arora,et al.  Contemporary strategies for the stabilization of peptides in the alpha-helical conformation. , 2008, Current opinion in chemical biology.

[3]  T. Earnest,et al.  Using fragment cocktail crystallography to assist inhibitor design of Trypanosoma brucei nucleoside 2-deoxyribosyltransferase. , 2006, Journal of medicinal chemistry.

[4]  Robert A. Weinberg,et al.  Ras oncogenes: split personalities , 2008, Nature Reviews Molecular Cell Biology.

[5]  Clemens Vonrhein,et al.  Exploiting structure similarity in refinement: automated NCS and target-structure restraints in BUSTER , 2012, Acta crystallographica. Section D, Biological crystallography.

[6]  M. Potashman,et al.  Covalent modifiers: an orthogonal approach to drug design. , 2009, Journal of medicinal chemistry.

[7]  A. Kalgutkar,et al.  Drug discovery for a new generation of covalent drugs , 2012, Expert opinion on drug discovery.

[8]  J. Cherfils,et al.  Structural snapshots of the mechanism and inhibition of a guanine nucleotide exchange factor , 2003, Nature.

[9]  Clemens Vonrhein,et al.  Data processing and analysis with the autoPROC toolbox , 2011, Acta crystallographica. Section D, Biological crystallography.

[10]  J. Andrew Grant,et al.  Small Molecule Shape-Fingerprints , 2005, J. Chem. Inf. Model..

[11]  Robert Mah,et al.  Drug discovery considerations in the development of covalent inhibitors. , 2014, Bioorganic & medicinal chemistry letters.

[12]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[13]  Andre Hoelz,et al.  Structural Evidence for Feedback Activation by Ras·GTP of the Ras-Specific Nucleotide Exchange Factor SOS , 2003, Cell.

[14]  C. Der,et al.  Specificity and Mechanism of Action of EHT 1864, a Novel Small Molecule Inhibitor of Rac Family Small GTPases* , 2007, Journal of Biological Chemistry.

[15]  J. Acker,et al.  Brefeldin A acts to stabilize an abortive ARF-GDP-Sec7 domain protein complex: involvement of specific residues of the Sec7 domain. , 1999, Molecular cell.

[16]  Qi Sun,et al.  Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. , 2012, Angewandte Chemie.

[17]  Randy J. Read,et al.  Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.

[18]  Fabrizio Giordanetto,et al.  Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties? , 2014, Journal of medicinal chemistry.

[19]  Philipp M. Cromm,et al.  Small-molecule modulation of Ras signaling. , 2014, Nature chemical biology.

[20]  Stefan G. Kathman,et al.  A Fragment-Based Method to Discover Irreversible Covalent Inhibitors of Cysteine Proteases , 2014, Journal of medicinal chemistry.

[21]  M. Broggini,et al.  RAS/RAF/MEK inhibitors in oncology. , 2012, Current medicinal chemistry.

[22]  Rutger H A Folmer,et al.  Fragment screening to predict druggability (ligandability) and lead discovery success. , 2011, Drug discovery today.

[23]  Taebo Sim,et al.  Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. , 2014, Angewandte Chemie.

[24]  I. Mellman,et al.  Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity , 2012, Proceedings of the National Academy of Sciences.

[25]  E. Olejniczak,et al.  Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange , 2014, Proceedings of the National Academy of Sciences.

[26]  Jon Winter,et al.  Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation. , 2012, Journal of medicinal chemistry.

[27]  B. Cravatt,et al.  Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. , 2010, Future medicinal chemistry.

[28]  Matthew Grist,et al.  Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR). , 2013, Journal of medicinal chemistry.

[29]  Kevan M. Shokat,et al.  K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions , 2013, Nature.

[30]  P. Macfaul,et al.  A simple in vitro assay for assessing the reactivity of nitrile containing compounds. , 2009, Bioorganic & medicinal chemistry letters.

[31]  John Kuriyan,et al.  The structural basis of the activation of Ras by Sos , 1998, Nature.

[32]  P. Arora,et al.  Contemporary Strategies for the Stabilization of Peptides in the α-Helical Conformation , 2009 .

[33]  K Wüthrich,et al.  Single Transition-to-single Transition Polarization Transfer (ST2-PT) in [15N,1H]-TROSY , 1998, Journal of biomolecular NMR.